DNA — Ginkgo Bioworks Holdings, Inc.

Summary of DNA Earnings Call (Q4 2025)

1. Key Financial Results and Metrics

• Cell Engineering Revenue: $26 million in Q4 2025, down 26% year-over-year; full-year revenue was $133 million, down from $174 million in 2024.
• Biosecurity Revenue: $7 million in Q4 2025; full-year revenue totaled $37 million.
• Adjusted EBITDA: Q4 2025 at negative $36 million, improved from negative $57 million in Q4 2024; full-year adjusted EBITDA at negative $167 million, improved from negative $293 million in 2024.
• Cash Burn: Q4 2025 cash burn was $47 million, down from $55 million in Q4 2024; full-year cash burn was $171 million, a 55% decrease from $383 million in 2024.

2. Strategic Updates and Business Highlights

• Focus on Autonomous Labs: The company is pivoting to invest heavily in autonomous labs, with plans to decommission traditional lab setups in favor of a centralized autonomous system in Boston.
• Divestiture of Biosecurity Business: Ginkgo plans to spin off its Biosecurity segment to focus resources on autonomous labs while retaining a minority stake.
• Partnerships and Contracts: Notable contracts include a $47 million deal with Pacific Northwest National Labs for building a 97-robot autonomous lab.
• Technological Advancements: Successful collaboration with OpenAI demonstrated the potential of AI in lab automation, achieving significant improvements in experimental outcomes.

3. Forward Guidance and Outlook

• 2026 Cash Burn Guidance: Expected to be between $125 million and $150 million, reflecting continued cost efficiency while investing in autonomous labs.
• Revenue Guidance: No specific revenue guidance provided for 2026; focus will be on cash burn as a more relevant metric for ongoing operations.
• Expansion Plans: Ginkgo aims to expand its autonomous lab capacity from 50 to 100 RACs (robotic automation carts) in Boston, enhancing service capabilities.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Both Cell Engineering and Biosecurity segments reported significant year-over-year revenue declines, raising concerns about overall business sustainability.
• Customer Program Rationalization: Ongoing restructuring efforts have led to a decrease in revenue-generating programs, impacting financial performance.
• Market Competition: The biotechnology sector is facing increased competition, particularly in the autonomous lab space, which may affect Ginkgo's market position.

5. Notable Q&A Insights

• Capacity Expansion and Revenue: The increase in RAC capacity is expected to facilitate more project-based services, but the exact contribution to revenue remains uncertain.
• Onshoring Manufacturing: There is potential for increased demand for RACs due to U.S. onshoring trends, particularly in quality control processes.
• Datapoints Offering: The Datapoints service is gaining traction among customers, with expectations for continued growth as it provides valuable data sets for bio AI models.
• Manufacturing Efficiency: Ginkgo is exploring strategies to enhance the production efficiency of RACs, including potential partnerships for larger-scale manufacturing.

Overall, while Ginkgo is making strategic moves towards autonomous labs and has improved its cash burn metrics, it faces challenges in revenue generation and market competition that could impact its growth trajectory.